Association of oncological response between the first‐line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma
Association of oncological response between the first‐line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma
复制标题
不可切除或转移性尿路上皮癌患者一线化疗与后续免疫检查点抑制剂治疗之间肿瘤学反应的关联
DOI:
10.1111/iju.14778
复制
发表时间:
2021
影响因子:
2.6
通讯作者:
Ohyama Chikara
中科院分区:
文献类型:
--
作者:
Ozaki Kai;Hatakeyama Shingo;Hamaya Tomoko;Okita Kazutaka;Hashimoto Yasuhiro;Ohyama Chikara
Abbreviations & Acronyms ICI immune checkpoint inhibitor OS overall survival PD progressive disease UC urothelial carcinoma Advanced UC is a life-threatening disease with a poor prognosis. 1-3 ICIs therapy is beneficial in patients with unresectable locally advanced or metastatic UC. 4, 5 However, limited biomarkers are available to predict the response to ICIs therapy.(d) Multivariable Cox regression analysis for OS in all patients (n= 218). gl The present results showed the favorable tumor response to the first-line chemotherapy (non-PD <= 4 cycles) was significantly associated with longer survival in patients with subsequent ICIs therapy than those without. Therefore, we retrospectively investigated the effect of tumor response to the first-line chemotherapy on the response to the subsequent ICIs therapy in patients with advanced UC.[Extracted from the article]Copyright of International Journal of Urology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. Copyright applies to all Abstracts.
影响因子:
2.6
作者:
A. Yamaguchi;K. Miwa;Kazuya Nakahira;Y. Moriyama;Y. Kitagawa
通讯作者:
Y. Kitagawa